Literature DB >> 1314177

Synergistic combination of azithromycin and sulfadiazine for treatment of toxoplasmosis in mice.

F G Araujo1, T Lin, J S Remington.   

Abstract

Experiments were performed in vivo in a mouse model of acute toxoplasmosis to evaluate the effectiveness of the combination azithromycin/sulfadiazine. Azithromycin alone or sulfadiazine alone, at doses that did not provide any protection against death due to toxoplasmosis, were remarkably and significantly synergistic against murine toxoplasmosis when administered in combination.

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1314177     DOI： 10.1007/bf01971278

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN： 0934-9723            Impact factor:   3.267


  15 in total

1.  An evaluation of the curative effects of pyrimethamine and sulfadiazine, alone and in combination, on experimental mouse toxoplasmosis.

Authors:  D E EYLES; N COLEMAN
Journal:  Antibiot Chemother (Northfield)       Date:  1955-10

2.  Treatment of toxoplasmic encephalitis with intravenous clindamycin.

Authors:  B R Dannemann; D M Israelski; J S Remington
Journal:  Arch Intern Med       Date:  1988-11

Review 3.  Toxoplasmic encephalitis in patients with AIDS.

Authors:  D M Israelski; J S Remington
Journal:  Infect Dis Clin North Am       Date:  1988-06       Impact factor: 5.982

Review 4.  AIDS commentary. Toxoplasmic encephalitis.

Authors:  B J Luft; J S Remington
Journal:  J Infect Dis       Date:  1988-01       Impact factor: 5.226

5.  Direct agglutination test for diagnosis of Toxoplasma infection: method for increasing sensitivity and specificity.

Authors:  G Desmonts; J S Remington
Journal:  J Clin Microbiol       Date:  1980-06       Impact factor: 5.948

6.  Interaction of sulfonamide and sulfone compounds with Toxoplasma gondii dihydropteroate synthase.

Authors:  C J Allegra; D Boarman; J A Kovacs; P Morrison; J Beaver; B A Chabner; H Masur
Journal:  J Clin Invest       Date:  1990-02       Impact factor: 14.808

7.  In vivo and in vitro activity of roxithromycin against Toxoplasma gondii in mice.

Authors:  B J Luft
Journal:  Eur J Clin Microbiol       Date:  1987-08       Impact factor: 3.267

8.  Pharmacokinetic and in vivo studies with azithromycin (CP-62,993), a new macrolide with an extended half-life and excellent tissue distribution.

Authors:  A E Girard; D Girard; A R English; T D Gootz; C R Cimochowski; J A Faiella; S L Haskell; J A Retsema
Journal:  Antimicrob Agents Chemother       Date:  1987-12       Impact factor: 5.191

9.  In vitro effects of four macrolides (roxithromycin, spiramycin, azithromycin [CP-62,993], and A-56268) on Toxoplasma gondii.

Authors:  H R Chang; J C Pechère
Journal:  Antimicrob Agents Chemother       Date:  1988-04       Impact factor: 5.191

10.  Assessment of therapy for toxoplasma encephalitis. The TE Study Group.

Authors:  H W Haverkos
Journal:  Am J Med       Date:  1987-05       Impact factor: 4.965
View more
  2 in total

1.  Atovaquone nanosuspensions show excellent therapeutic effect in a new murine model of reactivated toxoplasmosis.

Authors:  N Schöler; K Krause; O Kayser; R H Müller; K Borner; H Hahn; O Liesenfeld
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

2.  Lectins from Synadenium carinatum (ScLL) and Artocarpus heterophyllus (ArtinM) Are Able to Induce Beneficial Immunomodulatory Effects in a Murine Model for Treatment of Toxoplasma gondii Infection.

Authors:  Eliézer L P Ramos; Silas S Santana; Murilo V Silva; Fernanda M Santiago; Tiago W P Mineo; José R Mineo
Journal:  Front Cell Infect Microbiol       Date:  2016-11-25       Impact factor: 5.293
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.